STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #324 by analyst upside · 2026-06-27
LRMR
Larimar Therapeutics, Inc.
Healthcare · Market Cap $380M · P/E 0x
ANALYST PRICE TARGET
+312.9%
implied upside to consensus target
Current Price $3.66
Consensus Target $15.11
Bull Target $26.0
Bear Target $7.0
Analysts Covering 9
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
8
Hold
0
Sell
0
52-Week Low $2.71
52-Week High $6.42
YTD Return +5.5%
FUNDAMENTALS
Market Cap $380M
P/E Ratio (TTM) N/A
Forward P/E -3.0x
EPS (TTM) $-2.22
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.71
52-Week High $6.42
Current Price $3.66
Bear Target $7.0
Bull Target $26.0
● Now $3.66 ● Target $15.11
TRADING DATA
Avg Volume 1.7M
YTD Return +5.5%
Analyst Count 9
Consensus Buy
Upside to Target +312.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Larimar Therapeutics, Inc. (LRMR) is currently trading at $3.66 with a Wall Street consensus price target of $15.11, implying potential upside of 312.9% over the next 12 months. 9 analysts currently cover LRMR, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $26.0, while the most cautious has a target of $7.0.

LRMR operates in the Healthcare sector with a market capitalisation of $380M. The stock is up 5.5% year-to-date and is currently trading near the lower end of its 52-week range of $2.71 – $6.42.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LRMR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan ● Initiated
Overweight 2026-05-27 43% win rate (7 calls)
Wedbush — Reiterated
Outperform → Outperform 2026-05-18 Building track record
Wedbush — Reiterated
Outperform → Outperform 2026-03-20 Building track record
Wedbush — Reiterated
Outperform → Outperform 2026-03-03 Building track record
Citigroup — Reiterated
Buy → Buy 2026-02-25 Building track record
Wedbush reit
Outperform → Outperform 2026-02-25 Building track record
Oppenheimer — Reiterated
Outperform → Outperform 2025-10-02 14% win rate (7 calls)
Wedbush — Reiterated
Outperform → Outperform 2025-09-30 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →